Abstract
Oxycodone prolonged-release (PR) tablets provide a convenient twice-daily oral opioid option for the treatment of chronic pain, including cancer-related pain. Its analgesic efficacy in these settings has been established in clinical trials and extensive clinical practice and appears to be generally similar to that of oxycodone immediate release (IR) and long-acting oral formulations of other opioids. Oxycodone PR has a tolerability profile consistent with that of other opioids and is associated with less ‘drug liking’ and lower ‘drug highs’ than oxycodone IR when taken appropriately (i.e. as intact tablets, not crushed).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
